drugset / Trial / NCT00815633

A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris

NCT00815633

Phase 4 Terminated 1 enrolled Joshua Zeichner Astellas Pharma Inc · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether the biologic medication alefacept (Amevive) is effective and safe in the treatment of Pityriasis Rubra Pilaris.

Timeline

Start
2008-12
Primary completion
2009-06
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Alefacept Protein / enzyme biologic 15 mg Intramuscular